New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareVesilute vs Argireline

Vesilute vs Argireline

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Vesilute
Skin & Cosmetic
Argireline
Summary
Vesilute is a tetrapeptide bioregulator (Lys-Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific for the retina and visual system. It supports retinal cell function, promotes normalization of photoreceptor protein synthesis, and is studied for age-related macular degeneration (AMD), retinal aging, and vision preservation in the elderly.
Argireline is the most widely researched topical 'Botox-alternative' cosmetic peptide, an acetylated hexapeptide that inhibits neuromuscular transmission to relax facial muscles and reduce dynamic wrinkle depth by 17–27% in clinical studies.
Half-Life
Short (minutes); sustained gene-regulatory effects
N/A — topical application; effect duration linked to formulation contact time
Admin Route
SubQ, Oral
Topical
Research
Typical Dose
10 mg per day
5–10% concentration
Frequency
Daily for 10–30 days
Twice daily
Key Benefits
  • Supports retinal photoreceptor cell function and survival
  • May slow progression of age-related macular degeneration
  • Reduces retinal cell apoptosis from oxidative stress and aging
  • Anti-aging effects on retinal pigment epithelium
  • Potential support in diabetic retinopathy management
  • Preserves visual acuity with aging
  • Complementary to lutein, zeaxanthin, and NAD+ in ocular health protocols
  • Reduces depth of dynamic expression wrinkles 17–27%
  • Non-invasive topical Botox alternative
  • Smooths forehead, eye area, nasolabial fold lines
  • Widely studied — published clinical efficacy data
  • Synergistic with SNAP-8 for enhanced effect
  • Reduces fine lines around eyes (crow's feet)
  • Improves skin smoothness and texture
  • Well tolerated across all skin types
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant ocular adverse events reported at standard doses
  • Generally very well tolerated
  • At >10%: temporary eyelid/brow ptosis (drooping)
  • Rare: mild redness in sensitive skin
  • No systemic absorption at cosmetic doses
Stacks With